Altimmune, Inc.
Financials
Valuation Metrics
Altimmune, Inc.'s Market Cap is $391M. At end of 2025 it was $363M. Ranked #2819 of 3,118 in US market (top 90%), #1246 of 1,474 on NASDAQ (top 85%), #224 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 85%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $391M | US#2,819/3,118 Sec#224/265 |
| Revenue | $31000.00 | US#2,857/3,118 Sec#192/265 |
| Net Income | $-92M | US—/3,118 Sec—/265 |
| Total Assets | $527M | US#2,737/3,118 Sec#156/265 |
| Net Assets | $474M | US#2,253/3,118 Sec#111/265 |
| Employees | 57 | US#2,690/3,118 Sec#206/265 |
| Value | ||
| P/B | 0.82x | US#279/3,118 Sec#13/265 |
| P/S | 9533.98x | US#2,993/3,118 Sec#203/265 |
| FCF Yield | -19.59% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROE | -19.35% | US#2,465/3,118 Sec#99/265 |
| ROA | -17.40% | US#2,757/3,118 Sec#125/265 |
| Op. Margin | -323306.45% | US#2,857/3,118 Sec#192/265 |
| Revenue Growth | 55.00% | US#193/3,118 Sec#45/265 |
| Financial Health | ||
| Debt Ratio | 11.18% | US#121/3,118 Sec#54/265 |
| Total Debt | $36M | US#2,658/3,118 Sec#169/265 |
| FCF | $-77M | US#2,587/3,118 Sec#131/265 |
| Cash | $63M | US#2,469/3,118 Sec#211/265 |
| Current Ratio | 26.78x | US#89/3,118 Sec#13/265 |
| Performance | ||
| 1Y Return | -50.37% | US#2,867/3,118 Sec#235/265 |
| 1M Return | -26.64% | US#2,967/3,118 Sec#248/265 |
| From 52W High | -68.79% | US#2,950/3,118 Sec#235/265 |
| 1Y MDD | -67.48% | US#2,878/3,118 Sec#228/265 |
| Trading | ||
| Volume | 2,349,795 shares | US#651/3,118 Sec#51/265 |
| Trading Value | $5M | US#2,510/3,118 Sec#195/265 |
| Per Share | ||
| EPS | $-0.47 | US—/3,118 Sec—/265 |
| BPS | $2.44 | US#2,536/3,118 Sec#167/265 |
Company Info
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.